10% Owner · Inhibikase Therapeutics, Inc. · Common Stock
Side
BUY
Value
$3.00M
Shares
2.07M
Price
$1.45
Executed
Nov 21, 2025
Disclosed
Nov 24, 2025
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Nov 21 executedNov 24, 2025 disclosed
IKT · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Other disclosed activity · IKT
No records
No other disclosures for this security in the dataset.
Evidence
Verified data
Read directly from the primary public document; every field below is as reported by the filer.
Sands Capital Life Sciences Pulse Fund II, L.P. filed this Form 4 reporting a open-market purchase of IKT on Nov 21, 2025. It became public on Nov 24, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
10% Owner
Sands Capital Life Sciences Pulse Fund II, L.P.cik:0001875620
Issuer
Inhibikase Therapeutics, Inc.cik:0001750149
Revision history · 0
No field has changed since this record was first ingested.
